Affiliation:
1. Icahn School of Medicine at Mount Sinai
2. University Health Network
3. Weill Cornell Medical College/New York Presbyterian
4. Wake Forest University School of Medicine
5. Australian National University
6. UT Southwestern Medical Center at Dallas
Abstract
Abstract
Background
Up to 50% of men over 50 and 80% over 80 are affected by BPH. Shared decision-making regarding BPH treatment options can benefit from an improved understanding of relative risks and benefits for various treatments.
Methods
Data for this longitudinal retrospective population-based cohort study were obtained from a random sample of US Medicare and commercial claims (IBM Watson MarketScan) and restricted to men undergoing BPH surgery (TURP, PVP, PUL, WVTT) from 2015 to 2021 across all sites of service. Retreatments included Holmium laser enucleation and index procedures. Main outcomes were rates of retreatment and procedural complications over 1y, identified via CPT and ICD-9/10CM codes. Considered were procedural complications ≥1d post-index treatment and retreatment for patients with ≥1y data. Univariate cumulative incidence estimates, cumulative proportion and log-rank tests justified inclusion for covariate adjustment in Cox proportional hazard models.
Results
43,147 men diagnosed with BPH underwent 22,629 TURP, 11,392 PVP, 7,529 PUL, and 1,597 WVTT. At 1-year post-index: PUL was associated with the lowest rate of complication (PUL 15%, TURP 17%; PVP 19%, ; WVTT 26%); retreatment rates were not different (TURP 5.3%, PVP 5.3%, PUL 5.9%, WVTT 6.2%). At 5yr post-index: retreatment was lowest for TURP (7.0%) and was not significantly different between PVP and PUL (8.9% and 11.6%, respectively).
Conclusions
The results suggest that within one year of BPH surgery, one-in-twenty patients may require retreatment regardless of treatment choice, and for some technologies as many as one-in-four may require treatment for a complication.
Publisher
Research Square Platform LLC
Reference17 articles.
1. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States;Taub DA;Curr Urol Rep,2006
2. The Development of Human Benign Prostatic Hyperplasia with Age;Berry SJ;J Urol,1984
3. Lim SS, Vos T, Flaxman AD, et al: Global burden of disease study 2010: Design, Definitions and Metrics. Articles 2224 www.thelancet.com 2012; 3802229.
4. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK;Speakman M;BJU Int,2015
5. Cindolo L, Pirozzi L, Fanizza C, et al: Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-based Cohort Study. Eur Urol 2015; 68: 418–425. Available at: https://doi.org/10.1016/j.eururo.2014.11.006.